Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a novel drug called CUDC-907 as a possible treatment for
resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain
tumors.